Aarey Net Receivables vs Selling General Administrative Analysis

AAREYDRUGS

61.60 0.40 0.65%

Aarey Drugs financial indicator trend analysis is way more than just evaluating Aarey Drugs Pharmace prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aarey Drugs Pharmace is a good investment. Please check the relationship between Aarey Drugs Net Receivables and its Selling General Administrative accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aarey Drugs Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Net Receivables vs Selling General Administrative

Net Receivables vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aarey Drugs Pharmace Net Receivables account and Selling General Administrative. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Aarey Drugs' Net Receivables and Selling General Administrative is 0.49. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Aarey Drugs Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Aarey Drugs' Net Receivables and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Aarey Drugs Pharmaceuticals are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Net Receivables i.e., Aarey Drugs' Net Receivables and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.49

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Selling General Administrative

Most indicators from Aarey Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aarey Drugs Pharmace current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aarey Drugs Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

As of 12/11/2024, Selling General Administrative is likely to drop to about 3.5 M. In addition to that, Tax Provision is likely to drop to about 6.3 M

	2021	2022	2023	2024 (projected)
Gross Profit	195.4M	104.1M	136.7M	81.3M
Total Revenue	4.9B	4.1B	4.0B	2.7B

Gross Profit Total Revenue

Aarey Drugs fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Accounts Payable	Net Receivables	Current Deferred Revenue	Short Term Investments
Common Stock Shares Outstanding		0.9	0.61	0.47	0.83	0.92	0.86	0.62	0.73	-0.01	0.86	-0.22	-0.22	0.25	0.48	0.43	-0.13	0.81	0.83	0.9	0.99	0.58	0.76	0.85	0.68	0.35
Total Assets	0.9		0.76	0.53	0.97	0.96	0.85	0.77	0.85	0.13	0.96	-0.3	-0.38	0.28	0.67	0.56	-0.08	0.82	0.97	1.0	0.92	0.73	0.93	0.97	0.53	0.38
Short Long Term Debt Total	0.61	0.76		0.41	0.75	0.71	0.6	1.0	0.87	0.42	0.74	-0.23	-0.63	0.33	0.87	0.78	-0.11	0.78	0.76	0.76	0.63	0.99	0.72	0.82	0.14	0.03
Other Current Liab	0.47	0.53	0.41		0.39	0.64	0.6	0.41	0.59	0.04	0.61	0.08	-0.44	0.49	0.62	0.54	-0.53	0.63	0.41	0.53	0.48	0.35	0.34	0.49	0.52	0.17
Total Current Liabilities	0.83	0.97	0.75	0.39		0.85	0.75	0.75	0.77	0.22	0.89	-0.34	-0.36	0.28	0.61	0.5	0.04	0.71	1.0	0.97	0.85	0.71	0.98	0.93	0.4	0.32
Total Stockholder Equity	0.92	0.96	0.71	0.64	0.85		0.9	0.72	0.87	0.02	0.96	-0.23	-0.37	0.26	0.67	0.57	-0.21	0.88	0.86	0.96	0.93	0.68	0.8	0.93	0.62	0.43
Property Plant And Equipment Net	0.86	0.85	0.6	0.6	0.75	0.9		0.62	0.79	-0.01	0.91	-0.29	-0.2	0.22	0.53	0.4	-0.36	0.8	0.75	0.84	0.85	0.56	0.68	0.82	0.77	0.43
Net Debt	0.62	0.77	1.0	0.41	0.75	0.72	0.62		0.88	0.38	0.75	-0.24	-0.61	0.3	0.88	0.77	-0.12	0.78	0.76	0.77	0.64	0.99	0.72	0.83	0.16	0.04
Retained Earnings	0.73	0.85	0.87	0.59	0.77	0.87	0.79	0.88		0.25	0.87	-0.12	-0.65	0.38	0.84	0.81	-0.2	0.95	0.78	0.85	0.76	0.84	0.77	0.87	0.39	0.39
Cash	-0.01	0.13	0.42	0.04	0.22	0.02	-0.01	0.38	0.25		0.08	0.28	-0.66	0.66	0.25	0.55	0.09	0.23	0.22	0.14	0.05	0.42	0.24	0.15	-0.42	-0.19
Non Current Assets Total	0.86	0.96	0.74	0.61	0.89	0.96	0.91	0.75	0.87	0.08		-0.25	-0.37	0.26	0.71	0.55	-0.21	0.83	0.89	0.95	0.88	0.69	0.84	0.94	0.6	0.46
Non Currrent Assets Other	-0.22	-0.3	-0.23	0.08	-0.34	-0.23	-0.29	-0.24	-0.12	0.28	-0.25		-0.43	0.39	-0.23	0.25	0.3	0.01	-0.35	-0.31	-0.15	-0.25	-0.32	-0.43	-0.33	0.25
Other Assets	-0.22	-0.38	-0.63	-0.44	-0.36	-0.37	-0.2	-0.61	-0.65	-0.66	-0.37	-0.43		-0.66	-0.6	-0.95	-0.03	-0.64	-0.37	-0.38	-0.3	-0.61	-0.4	-0.4	0.28	-0.08
Cash And Short Term Investments	0.25	0.28	0.33	0.49	0.28	0.26	0.22	0.3	0.38	0.66	0.26	0.39	-0.66		0.42	0.65	-0.15	0.5	0.28	0.28	0.29	0.27	0.3	0.27	0.11	0.11
Non Current Liabilities Total	0.48	0.67	0.87	0.62	0.61	0.67	0.53	0.88	0.84	0.25	0.71	-0.23	-0.6	0.42		0.77	-0.34	0.76	0.63	0.67	0.5	0.83	0.59	0.76	0.26	0.11
Inventory	0.43	0.56	0.78	0.54	0.5	0.57	0.4	0.77	0.81	0.55	0.55	0.25	-0.95	0.65	0.77		-0.14	0.82	0.51	0.55	0.5	0.76	0.51	0.59	-0.04	0.1
Other Current Assets	-0.13	-0.08	-0.11	-0.53	0.04	-0.21	-0.36	-0.12	-0.2	0.09	-0.21	0.3	-0.03	-0.15	-0.34	-0.14		-0.26	0.03	-0.07	-0.08	-0.09	0.12	-0.16	-0.47	0.25
Other Stockholder Equity	0.81	0.82	0.78	0.63	0.71	0.88	0.8	0.78	0.95	0.23	0.83	0.01	-0.64	0.5	0.76	0.82	-0.26		0.72	0.82	0.84	0.75	0.69	0.82	0.49	0.4
Total Liab	0.83	0.97	0.76	0.41	1.0	0.86	0.75	0.76	0.78	0.22	0.89	-0.35	-0.37	0.28	0.63	0.51	0.03	0.72		0.97	0.85	0.72	0.98	0.94	0.41	0.31
Total Current Assets	0.9	1.0	0.76	0.53	0.97	0.96	0.84	0.77	0.85	0.14	0.95	-0.31	-0.38	0.28	0.67	0.55	-0.07	0.82	0.97		0.92	0.73	0.93	0.97	0.52	0.37
Common Stock	0.99	0.92	0.63	0.48	0.85	0.93	0.85	0.64	0.76	0.05	0.88	-0.15	-0.3	0.29	0.5	0.5	-0.08	0.84	0.85	0.92		0.61	0.79	0.86	0.62	0.39
Short Term Debt	0.58	0.73	0.99	0.35	0.71	0.68	0.56	0.99	0.84	0.42	0.69	-0.25	-0.61	0.27	0.83	0.76	-0.09	0.75	0.72	0.73	0.61		0.68	0.79	0.08	-0.04
Accounts Payable	0.76	0.93	0.72	0.34	0.98	0.8	0.68	0.72	0.77	0.24	0.84	-0.32	-0.4	0.3	0.59	0.51	0.12	0.69	0.98	0.93	0.79	0.68		0.9	0.34	0.37
Net Receivables	0.85	0.97	0.82	0.49	0.93	0.93	0.82	0.83	0.87	0.15	0.94	-0.43	-0.4	0.27	0.76	0.59	-0.16	0.82	0.94	0.97	0.86	0.79	0.9		0.48	0.27
Current Deferred Revenue	0.68	0.53	0.14	0.52	0.4	0.62	0.77	0.16	0.39	-0.42	0.6	-0.33	0.28	0.11	0.26	-0.04	-0.47	0.49	0.41	0.52	0.62	0.08	0.34	0.48		0.45
Short Term Investments	0.35	0.38	0.03	0.17	0.32	0.43	0.43	0.04	0.39	-0.19	0.46	0.25	-0.08	0.11	0.11	0.1	0.25	0.4	0.31	0.37	0.39	-0.04	0.37	0.27	0.45

Click cells to compare fundamentals

Aarey Drugs Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Aarey Stock Analysis

When running Aarey Drugs' price analysis, check to measure Aarey Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarey Drugs is operating at the current time. Most of Aarey Drugs' value examination focuses on studying past and present price action to predict the probability of Aarey Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarey Drugs' price. Additionally, you may evaluate how the addition of Aarey Drugs to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aarey Net Receivables vs Selling General Administrative Analysis

Net Receivables vs Selling General Administrative

Net Receivables vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Net Receivables

Selling General Administrative

Aarey Drugs fundamental ratios Correlations

Aarey Drugs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Aarey Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Total Current Liabilities
Common Stock	+ 0.99	Common Stock Shares Outstanding
Short Term Debt	+ 0.99	Short Long Term Debt Total
Short Term Debt	+ 0.99	Net Debt

Inventory	- 0.95	Other Assets
Cash And Short Term Investments	- 0.66	Other Assets
Other Assets	- 0.66	Cash
Other Assets	- 0.65	Retained Earnings
Other Stockholder Equity	- 0.64	Other Assets
Other Assets	- 0.63	Short Long Term Debt Total